Literature DB >> 12460994

Resistance surveillance studies--comparability of results and quality assurance of methods.

Gunnar Kahlmeter1, Derek F J Brown.   

Abstract

Mesh：

Year:  2002        PMID： 12460994     DOI： 10.1093/jac/dkg041

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


× No keyword cloud information.
  5 in total

1.  Normalized resistance interpretation as a tool for establishing epidemiological MIC susceptibility breakpoints.

Authors:  Göran Kronvall
Journal:  J Clin Microbiol       Date:  2010-10-06       Impact factor: 5.948

2.  Comparison of results of voriconazole disk diffusion testing for Candida species with results from a central reference laboratory in the ARTEMIS global antifungal surveillance program.

Authors:  M A Pfaller; L Boyken; S A Messer; S Tendolkar; R J Hollis; D J Diekema
Journal:  J Clin Microbiol       Date:  2005-10       Impact factor: 5.948

3.  Results from the ARTEMIS DISK Global Antifungal Surveillance Study: a 6.5-year analysis of susceptibilities of Candida and other yeast species to fluconazole and voriconazole by standardized disk diffusion testing.

Authors:  M A Pfaller; D J Diekema; M G Rinaldi; R Barnes; B Hu; A V Veselov; N Tiraboschi; E Nagy; D L Gibbs
Journal:  J Clin Microbiol       Date:  2005-12       Impact factor: 5.948

4.  Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida Species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion.

Authors:  M A Pfaller; D J Diekema; D L Gibbs; V A Newell; D Ellis; V Tullio; A Rodloff; W Fu; T A Ling
Journal:  J Clin Microbiol       Date:  2010-02-17       Impact factor: 5.948

5.  Comparison of results of fluconazole disk diffusion testing for Candida species with results from a central reference laboratory in the ARTEMIS global antifungal surveillance program.

Authors:  M A Pfaller; K C Hazen; S A Messer; L Boyken; S Tendolkar; R J Hollis; D J Diekema
Journal:  J Clin Microbiol       Date:  2004-08       Impact factor: 5.948
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.